Items related to Benefit-Risk Appraisal of Medicines: A Systematic Approach...
Benefit-risk assessment is at the centre of the approval process for every new medicine. The ability to assess the risks of a new medicine accurately and to balance these against the benefits the medicine could bring is critical for every regulatory authority and pharmaceutical company. Despite this there are very few tried and tested evaluative models currently available.
The authors of this book have developed a new, pioneering tool for the assessment of benefits and risks for new medicines in development. This model utilises a multi-criteria decision analysis which involves selecting, scoring and weighting key benefit and risk attributes and leads to an overall appraisal of benefits and risks of medicines.
Benefit-Risk Appraisal of Medicines establishes the background and criteria required to assess benefit and risk in general and reviews the current practices by regulatory authorities and the pharmaceutical industry, including those models currently available. It outlines the development and evaluation of the authors’ new model and analyses the implications of its implementation.
- Describes an innovative, systematic model which leads to transparent and responsible benefit-risk decision making
- Contributes important ideas to the debate on benefit-risk appraisal
- Provides a future framework for benefit-risk appraisal of medicines
Benefit-Risk Appraisal of Medicines covers the entire process from the discovery of new medicines to their marketing and is ideal for all those who work in the pharmaceutical industry and regulatory authorities,, as well as post-graduate students of pharmaceutical medicine and clinical pharmacology.
"synopsis" may belong to another edition of this title.
About the Author:
Dr Sam Salek, Reader in Pharmacoepidemiology, Director - WSP Centre for Socioeconomic Research; Director - Postgraduate Course in Pharmaceutical Medicine, Cardiff University, UK.
Mr Filip Mussen, Johnson & Johnson Pharmaceuticals Research and Development, Belgium.
Prof Stuart Walker, President and Founder, International Institute for Regulatory Science, UK.
"About this title" may belong to another edition of this title.
- PublisherJohn Wiley & Sons Inc
- Publication date2010
- ISBN 10 0470060859
- ISBN 13 9780470060858
- BindingHardcover
- Number of pages294
Buy New
Learn more about this copy
US$ 78.82
Shipping:
US$ 5.17
Within U.S.A.
Top Search Results from the AbeBooks Marketplace
Stock Image
BENEFIT-RISK APPRAISAL OF MEDICI
Published by
John Wiley & Sons Inc
(2010)
ISBN 10: 0470060859
ISBN 13: 9780470060858
New
Hardcover
Quantity: 1
Seller:
Rating
Book Description Condition: New. New. In shrink wrap. Looks like an interesting title! 1.41. Seller Inventory # Q-0470060859
Buy New
US$ 78.82
Convert currency
Seller Image
Benefit-Risk Appraisal of Medicines : A Systematic Approach to Decision-Making
Published by
John Wiley & Sons Inc
(2010)
ISBN 10: 0470060859
ISBN 13: 9780470060858
New
Hardcover
Quantity: 4
Seller:
Rating
Book Description Condition: New. Seller Inventory # 4402442-n
Buy New
US$ 120.18
Convert currency
Seller Image
Benefit-Risk Appraisal of Medicines: A systematic approach to decision-making by Mussen, Filip, Salek, Sam, Walker, Stuart [Hardcover ]
Seller:
Rating
Book Description Hardcover. Condition: new. Seller Inventory # 9780470060858
Buy New
US$ 122.83
Convert currency
Stock Image
Benefit-Risk Appraisal of Medicines: A systematic approach to decision-making Format: Hardcover
Published by
John Wiley and Sons
(2010)
ISBN 10: 0470060859
ISBN 13: 9780470060858
New
Hardcover
Quantity: > 20
Seller:
Rating
Book Description Condition: New. Brand New. Seller Inventory # 9780470060858
Buy New
US$ 124.92
Convert currency
Seller Image
Benefit-Risk Appraisal of Medicines : A Systematic Approach to Decision-Making
Published by
John Wiley & Sons Inc
(2010)
ISBN 10: 0470060859
ISBN 13: 9780470060858
New
Hardcover
Quantity: 4
Seller:
Rating
Book Description Condition: New. Seller Inventory # 4402442-n
Buy New
US$ 128.63
Convert currency
Seller Image
Benefit-Risk Appraisal of Medicines (Hardcover)
Published by
John Wiley & Sons Inc, New York
(2009)
ISBN 10: 0470060859
ISBN 13: 9780470060858
New
Hardcover
First Edition
Quantity: 1
Seller:
Rating
Book Description Hardcover. Condition: new. Hardcover. Benefit-risk assessment is at the centre of the approval process for every new medicine. The ability to assess the risks of a new medicine accurately and to balance these against the benefits the medicine could bring is critical for every regulatory authority and pharmaceutical company. Despite this there are very few tried and tested evaluative models currently available. The authors of this book have developed a new, pioneering tool for the assessment of benefits and risks for new medicines in development. This model utilises a multi-criteria decision analysis which involves selecting, scoring and weighting key benefit and risk attributes and leads to an overall appraisal of benefits and risks of medicines. Benefit-Risk Appraisal of Medicines establishes the background and criteria required to assess benefit and risk in general and reviews the current practices by regulatory authorities and the pharmaceutical industry, including those models currently available. It outlines the development and evaluation of the authors new model and analyses the implications of its implementation. Describes an innovative, systematic model which leads to transparent and responsible benefit-risk decision makingContributes important ideas to the debate on benefit-risk appraisalProvides a future framework for benefit-risk appraisal of medicines Benefit-Risk Appraisal of Medicines covers the entire process from the discovery of new medicines to their marketing and is ideal for all those who work in the pharmaceutical industry and regulatory authorities, as well as post-graduate students of pharmaceutical medicine and clinical pharmacology. Establishes the criteria required to assess benefit-risk in general and reviews the current practice of benefit-risk assessment by drug regulatory authorities and the pharmaceutical industry. Outlines how the new MCDA model was developed and evaluated, and discusses the implications of its implementation into the practice of drug evaluation. Shipping may be from multiple locations in the US or from the UK, depending on stock availability. Seller Inventory # 9780470060858
Buy New
US$ 160.49
Convert currency
Seller Image
Benefit-Risk Appraisal of Medicines
Published by
John Wiley & Sons
(2009)
ISBN 10: 0470060859
ISBN 13: 9780470060858
New
Hardcover
Quantity: 3
Seller:
Rating
Book Description Gebunden. Condition: New. Benefit-risk assessment is at the centre of the approval process for every new medicine. The ability to assess the risks of a new medicine accurately and to balance these against the benefits the medicine could bring is critical for every regulatory authori. Seller Inventory # 5917315
Buy New
US$ 111.15
Convert currency
Stock Image
Benefit-Risk Appraisal of Medicines: A Systematic Approach to Decision-Making
Published by
John Wiley & Sons Inc
(2010)
ISBN 10: 0470060859
ISBN 13: 9780470060858
New
Hardcover
Quantity: > 20
Seller:
Rating
Book Description Condition: New. Brand new! Please provide a physical shipping address. Seller Inventory # 9780470060858
Buy New
US$ 182.12
Convert currency
Seller Image
Benefit-Risk Appraisal of Medicines (Hardcover)
Published by
John Wiley & Sons Inc, New York
(2009)
ISBN 10: 0470060859
ISBN 13: 9780470060858
New
Hardcover
First Edition
Quantity: 1
Seller:
Rating
Book Description Hardcover. Condition: new. Hardcover. Benefit-risk assessment is at the centre of the approval process for every new medicine. The ability to assess the risks of a new medicine accurately and to balance these against the benefits the medicine could bring is critical for every regulatory authority and pharmaceutical company. Despite this there are very few tried and tested evaluative models currently available. The authors of this book have developed a new, pioneering tool for the assessment of benefits and risks for new medicines in development. This model utilises a multi-criteria decision analysis which involves selecting, scoring and weighting key benefit and risk attributes and leads to an overall appraisal of benefits and risks of medicines. Benefit-Risk Appraisal of Medicines establishes the background and criteria required to assess benefit and risk in general and reviews the current practices by regulatory authorities and the pharmaceutical industry, including those models currently available. It outlines the development and evaluation of the authors new model and analyses the implications of its implementation. Describes an innovative, systematic model which leads to transparent and responsible benefit-risk decision makingContributes important ideas to the debate on benefit-risk appraisalProvides a future framework for benefit-risk appraisal of medicines Benefit-Risk Appraisal of Medicines covers the entire process from the discovery of new medicines to their marketing and is ideal for all those who work in the pharmaceutical industry and regulatory authorities, as well as post-graduate students of pharmaceutical medicine and clinical pharmacology. Establishes the criteria required to assess benefit-risk in general and reviews the current practice of benefit-risk assessment by drug regulatory authorities and the pharmaceutical industry. Outlines how the new MCDA model was developed and evaluated, and discusses the implications of its implementation into the practice of drug evaluation. Shipping may be from our UK warehouse or from our Australian or US warehouses, depending on stock availability. Seller Inventory # 9780470060858
Buy New
US$ 184.19
Convert currency
Seller Image
Benefit-Risk Appraisal of Medicines (Hardcover)
Published by
John Wiley & Sons Inc, New York
(2009)
ISBN 10: 0470060859
ISBN 13: 9780470060858
New
Hardcover
First Edition
Quantity: 1
Seller:
Rating
Book Description Hardcover. Condition: new. Hardcover. Benefit-risk assessment is at the centre of the approval process for every new medicine. The ability to assess the risks of a new medicine accurately and to balance these against the benefits the medicine could bring is critical for every regulatory authority and pharmaceutical company. Despite this there are very few tried and tested evaluative models currently available. The authors of this book have developed a new, pioneering tool for the assessment of benefits and risks for new medicines in development. This model utilises a multi-criteria decision analysis which involves selecting, scoring and weighting key benefit and risk attributes and leads to an overall appraisal of benefits and risks of medicines. Benefit-Risk Appraisal of Medicines establishes the background and criteria required to assess benefit and risk in general and reviews the current practices by regulatory authorities and the pharmaceutical industry, including those models currently available. It outlines the development and evaluation of the authors new model and analyses the implications of its implementation. Describes an innovative, systematic model which leads to transparent and responsible benefit-risk decision makingContributes important ideas to the debate on benefit-risk appraisalProvides a future framework for benefit-risk appraisal of medicines Benefit-Risk Appraisal of Medicines covers the entire process from the discovery of new medicines to their marketing and is ideal for all those who work in the pharmaceutical industry and regulatory authorities, as well as post-graduate students of pharmaceutical medicine and clinical pharmacology. Establishes the criteria required to assess benefit-risk in general and reviews the current practice of benefit-risk assessment by drug regulatory authorities and the pharmaceutical industry. Outlines how the new MCDA model was developed and evaluated, and discusses the implications of its implementation into the practice of drug evaluation. Shipping may be from our Sydney, NSW warehouse or from our UK or US warehouse, depending on stock availability. Seller Inventory # 9780470060858
Buy New
US$ 203.17
Convert currency